Filing Analysis
Pulmatrix, Inc. announced the closing of a private placement of its Series B Preferred Stock on April 16, 2026. The transaction was conducted under registration exemptions and disclosed via a press release on April 21, 2026.
Red Flags
- Interim leadership: Peter Ludlum is serving as both Interim CEO and Interim CFO, suggesting management instability
- Issuance of Series B Preferred Stock often involves dilutive terms or liquidation preferences that disadvantage common stockholders
Key Facts
- Closed a private placement of Series B Preferred Stock on April 16, 2026
- The offering was exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D
- Peter Ludlum is currently serving as both Interim CEO and Interim CFO
- The company issued a press release regarding the closing on April 21, 2026
Pulmatrix, Inc. has entered into a definitive merger agreement with Eos SENOLYTIX, Inc. in a reverse merger transaction that will result in Eos stockholders owning approximately 94% of the combined company. The transaction involves a total change of control, a name change to Eos SENOLYTIX, Inc., and a proposed reverse stock split.
Red Flags
- Extreme dilution of existing shareholders (retaining only 6% ownership).
- Proposed reverse stock split to maintain Nasdaq compliance or facilitate the merger.
- Total change of control with Eos designating 5 out of 6 board members.
- The company is essentially serving as a shell for a private entity's public debut.
Key Facts
- Merger agreement signed on March 26, 2026, with Eos SENOLYTIX, Inc.
- Post-merger ownership split is approximately 94% for Eos stockholders and 6% for Pulmatrix stockholders.
- Pulmatrix will issue Series B Convertible Preferred Stock to an Eos affiliate for $1,000,000 in gross proceeds.
- The combined company's board will consist of six members, five of whom will be designated by Eos.
- The company will seek stockholder approval for a name change and a reverse stock split.
- A lock-up agreement restricts the sale of shares by the primary Eos stockholder for 180 days post-closing.
Pulmatrix, Inc. received a termination notice from Cullgen Inc. regarding their previously announced Merger Agreement and Plan of Reorganization. The deal, which had been in progress since November 2024, was terminated without any termination fees, leaving Pulmatrix to bear its own transaction costs.
Red Flags
- Termination of a major strategic merger that had been pending for over 15 months.
- Company is currently operating under interim leadership (Interim CEO/CFO).
- Potential loss of a primary strategic path for the company's future operations or exit.
Key Facts
- Termination notice received from Cullgen Inc. on February 28, 2026.
- The original Merger Agreement was dated November 13, 2024, and amended April 7, 2025.
- No termination fees are required to be paid by either party.
- Pulmatrix and Cullgen will each bear their own respective costs and expenses related to the failed merger.
- The filing was signed by Peter Ludlum, who is serving as both Interim CEO and Interim CFO.
Pulmatrix, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release. The report was signed by Peter Ludlum, who is currently serving in a dual capacity as both Interim CEO and Interim CFO.
Red Flags
- Management instability: The company is operating with an individual serving as both Interim CEO and Interim CFO, which may indicate a lack of permanent leadership or difficulty in recruiting executive talent.
Key Facts
- Released financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Peter Ludlum is currently holding both the Interim Chief Executive Officer and Interim Chief Financial Officer positions.